
Eeva K Broberg

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8470762/publications.pdf Version: 2024-02-01



FEVA K ROOBERC

#	Article	IF	CITATIONS
1	Seasonality of respiratory syncytial virus and its association with meteorological factors in 13 European countries, week 40 2010 to week 39 2019. Eurosurveillance, 2022, 27, .	7.0	18
2	Recommendations for respiratory syncytial virus surveillance at the national level. European Respiratory Journal, 2021, 58, 2003766.	6.7	33
3	Molecular Epidemiology and Evolutionary Trajectory of Emerging Echovirus 30, Europe. Emerging Infectious Diseases, 2021, 27, 1616-1626.	4.3	18
4	Meta-analysis of the clinical performance of commercial SARS-CoV-2 nucleic acid and antibody tests up to 22 August 2020. Eurosurveillance, 2021, 26, .	7.0	10
5	Circulation of non-polio enteroviruses in 24 EU and EEA countries between 2015 and 2017: a retrospective surveillance study. Lancet Infectious Diseases, The, 2020, 20, 350-361.	9.1	76
6	Geographical and temporal distribution of SARS-CoV-2 clades in the WHO European Region, January to June 2020. Eurosurveillance, 2020, 25, .	7.0	186
7	Piloting a surveillance system for HIV drug resistance in the European Union. Eurosurveillance, 2019, 24, .	7.0	10
8	Current practices for respiratory syncytial virus surveillance across the EU/EEA Member States, 2017. Eurosurveillance, 2019, 24, .	7.0	13
9	Recommendations for enterovirus diagnostics and characterisation within and beyond Europe. Journal of Clinical Virology, 2018, 101, 11-17.	3.1	161
10	Upsurge in echovirus 30 detections in five EU/EEA countries, April to September, 2018. Eurosurveillance, 2018, 23, .	7.0	32
11	Seasonality and geographical spread of respiratory syncytial virus epidemics in 15 European countries, 2010 to 2016. Eurosurveillance, 2018, 23, .	7.0	89
12	Predominance of influenza A(H3N2) virus genetic subclade 3C.2a1 during an early 2016/17 influenza season in Europe – Contribution of surveillance data from World Health Organization (WHO) European Region to the WHO vaccine composition consultation for northern hemisphere 2017/18. Vaccine, 2017, 35, 4828-4835.	3.8	14
13	Surveillance and laboratory detection for non-polio enteroviruses in the European Union/European Economic Area, 2016. Eurosurveillance, 2017, 22, .	7.0	33
14	Assessment of HIV molecular surveillance capacity in the European Union, 2016. Eurosurveillance, 2017, 22, .	7.0	5
15	Seasonality of respiratory syncytial virus infection in the EU/EEA, 2010–2016. Journal of Clinical Virology, 2016, 82, S116-S117.	3.1	2
16	Predominance of influenza A(H1N1)pdm09 virus genetic subclade 6B.1 and influenza B/Victoria lineage viruses at the start of the 2015/16 influenza season in Europe. Eurosurveillance, 2016, 21, .	7.0	37
17	Improving influenza virological surveillance in Europe: strain-based reporting of antigenic and genetic characterisation data, 11 European countries, influenza season 2013/14. Eurosurveillance, 2016, 21, .	7.0	12
18	No evidence of human herpesvirus DNA in the CSF of multiple sclerosis patients. Neurological Sciences, 2015, 36, 1053-1054.	1.9	0

Eeva K Broberg

#	Article	IF	CITATIONS
19	Why should influenza be a public health priority?. Vaccine, 2015, 33, 7022-7025.	3.8	6
20	Influenza serological studies to inform public health action: best practices to optimise timing, quality and reporting. Influenza and Other Respiratory Viruses, 2013, 7, 211-224.	3.4	45
21	The consortium for the standardization of influenza seroepidemiology (CONSISE): a global partnership to standardize influenza seroepidemiology and develop influenza investigation protocols to inform public health policy. Influenza and Other Respiratory Viruses, 2013, 7, 231-234.	3.4	37
22	Guidance for clinical and public health laboratories testing for influenza virus antiviral drug susceptibility in Europe. Journal of Clinical Virology, 2013, 57, 5-12.	3.1	27
23	Pandemic influenza A (H1N1) virus in households with young children. Influenza and Other Respiratory Viruses, 2012, 6, e21-4.	3.4	6
24	Surveillance of hospitalised severe cases of influenza A(H1N1)pdm09 and related fatalities in nine EU countries in 2010–2011. Influenza and Other Respiratory Viruses, 2012, 6, e93-6.	3.4	13
25	Human rhinovirus C—Associated severe pneumonia in a neonate. Journal of Clinical Virology, 2011, 51, 79-82.	3.1	33
26	Seroprevalence to Influenza A(H1N1) 2009 Virus—Where Are We?. Vaccine Journal, 2011, 18, 1205-1212.	3.1	60
27	Genetic engineering of a modified herpes simplex virus 1 vaccine vector. Vaccine, 2009, 27, 2760-2767.	3.8	31
28	Herpes Simplex Virus Type 1 Us3 Gene Deletion Influences Toll-like Receptor Responses in Cultured Monocytic Cells. Virology Journal, 2008, 5, 140.	3.4	64
29	Enhancement of Th2 responses to replicative herpes simplex virus type 1 vectors by immunomodulative chemotherapy. International Immunopharmacology, 2006, 6, 817-829.	3.8	5
30	Immune Response to Herpes Simplex Virus and γ134.5 Deleted HSV Vectors. Current Gene Therapy, 2005, 5, 523-530.	2.0	27
31	Spread and Replication of and Immune Response to γ 1 34.5-Negative Herpes Simplex Virus Type 1 Vectors in BALB/c Mice. Journal of Virology, 2004, 78, 13139-13152.	3.4	30
32	IL-4 is the key regulator in herpes simplex virus-based gene therapy of BALB/c experimental autoimmune encephalomyelitis. Neuroscience Letters, 2004, 364, 173-178.	2.1	33
33	Low copy number detection of herpes simplex virus type 1 mRNA and mouse Th1 type cytokine mRNAs by Light Cycler quantitative real-time PCR. Journal of Virological Methods, 2003, 112, 53-65.	2.1	30
34	Herpesviruses in brains in Alzheimer's and Parkinson's diseases. Annals of Neurology, 2003, 54, 267-271.	5.3	114
35	Herpes Simplex Virus Type 1 Infection Induces Upregulation of Interleukin-23 (p19) mRNA Expression in Trigeminal Ganglia of BALB/c Mice. Journal of Interferon and Cytokine Research, 2002, 22, 641-651.	1.2	28
36	CYTOKINES IN EXPERIMENTAL HERPES SIMPLEX VIRUS INFECTION. International Reviews of Immunology, 2002, 21, 355-371.	3.3	25